Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Immunoglobulin therapy, specifically intravenous immunoglobulin (IVIG), is supported by substantial scientific evidence for the treatment of various autoimmune disorders. IVIG consists of pooled IgG antibodies extracted from the plasma of thousands of healthy donors. Its use is well-established in conditions such as immune thrombocytopenic purpura (ITP), Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis, among others. Clinical trials and consensus guidelines have demonstrated that IVIG can modulate the immune response, likely via mechanisms such as Fc receptor blockade, modulation of complement activation, neutralization of pathogenic autoantibodies, and effects on cytokine production and regulatory T cells. These immunomodulatory actions help reduce tissue damage caused by autoimmune processes.

The efficacy of IVIG is supported by randomized controlled trials and systematic reviews, especially for conditions like ITP and CIDP. For some other autoimmune disorders, such as systemic lupus erythematosus or multiple sclerosis, the evidence is less robust, and IVIG is typically reserved for refractory cases or when standard therapies are contraindicated. Major guidelines, such as those from the American Academy of Neurology and the American Society of Hematology, include IVIG as a recommended or alternative therapy for specific autoimmune conditions. Adverse effects are generally mild but can include infusion reactions and, rarely, thromboembolic events.

In summary, IVIG is a scientifically validated, effective, and guideline-supported therapy for several autoimmune diseases, though its use is often restricted to specific indications based on the strength of available evidence.

More about immunoglobulin
More about Autoimmune Disorders

Other ingredients used for Autoimmune Disorders

Other health conditions supported by immunoglobulin

Products containing immunoglobulin